Research Paper Volume 12, Issue 4 pp 3848—3861
Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation
Figure 2. Characteristics of the hormone-naïve D17225 PDX model. (A–C) Factors influencing the establishment of the PDX model. (A) Change in testosterone levels in androgen-implanted mice. (B) Effect of supplementation with androgen on PC tumor growth. (C) Effect of supplementation with androgen on the growth latency of the PC tumor. Results are shown as the means ± SD (n = 5). (D–E) Induction of CRPC in the D17225 PDX model. (D) Tumor volumes of D17225 xenografts and mouse serum PSA levels at various time points before, during, and after castration-induced CRPC development. (E) H&E staining of D17225 tumor sections, and the levels of AR and PSA in tumor sections (IHC analysis) at various time points before and after host castration and in recurrent tumors. The scale bar indicates 100 mm. Cx indicates castration weeks.